TY  - JOUR
AU  - Santos, C
AU  - Azuara, D
AU  - Vieitez, J M
AU  - Paez, D
AU  - Falco, E
AU  - Elez, E
AU  - Lopez-Lopez, C
AU  - Valladares, M
AU  - Robles-Diaz, L
AU  - Garcia-Alfonso, P
AU  - Buges, C
AU  - Duran, G
AU  - Salud, A
AU  - Navarro, V
AU  - Capella, G
AU  - Aranda, E
AU  - Salazar, R
PY  - 2019
DO  - 10.1093/annonc/mdz082
UR  - http://hdl.handle.net/10668/13664
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations because benefits of anti-EGFR therapies may depend on certain sensitivity thresholds. We assessed whether ultra-selection of patients using a...
LA  - en
PB  - Elsevier
KW  - FOLFIRI
KW  - PCR
KW  - Digital PCR
KW  - Metastatic colorectal cancer
KW  - Panitumumab
KW  - Patient selection
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic combined chemotherapy protocols
KW  - Biomarkers, tumor
KW  - Camptothecin
KW  - Class I phosphatidylinositol 3-kinases
KW  - Colorectal neoplasms
KW  - Fluorouracil
KW  - GTP phosphohydrolases
KW  - Genotype
KW  - Humans
KW  - Leucovorin
KW  - Male
KW  - Membrane proteins
KW  - Middle aged
KW  - Neoplasm metastasis
KW  - Panitumumab
KW  - Prospective studies
KW  - Proto-oncogene proteins B-raf
KW  - Proto-oncogene proteins p21(ras)
KW  - Survival rate
TI  - Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
TY  - research article
VL  - 30
ER  -